Skip to main content

Volume 6 Supplement 2

Current and new antitumor necrosis factor agents in perspective


Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Centocor, Inc.

  1. Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which str...

    Authors: David Yocum
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S24
  2. Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis. Genetic...

    Authors: Paul M Peloso and Jürgen Braun
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S36
  3. Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate to s...

    Authors: Alice B Gottlieb and Christian E Antoni
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S31

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    111 days submission to accept (Median)

    2023 Usage 
    1,885 Altmetric mentions